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ABSTRACT
Introduction Our aim was to assess the association 
between casual blood glucose level and subsequent 
cardiovascular disease (CVD) and mortality among 
community- dwelling adults without a diagnosis of 
diabetes.
Research design and methods In this community- based 
cohort study, 159 731 individuals with a measurement of 
casual blood glucose were followed from their participation 
date in Cohort of Norway (CONOR) (1994–2003) until a 
CVD episode, death or 31 December 2009. All analyses 
were done using Cox proportional hazard regression, and 
the results are reported as multivariable- adjusted HRs with 
95% CI.
Results Compared with those with normal glucose 
levels (<7.8 mmol/L), participants categorized as having 
borderline (7.8–11.0 mmol/L) levels showed an increased 
risk of a stroke (HR 1.29; 95% CI 1.12 to 2.49) and 
cardiovascular (HR 1.29; 95% CI 1.12 to 2.48), and all- 
cause (HR 1.27; 95% CI 1.16 to 1.38) mortality, while 
participants with high glucose levels (>11.0 mmol/L) had 
an even more increased risk. One mmol/L increase in 
glucose level was associated with an increased risk of all 
four endpoints among participants with borderline as well 
as within normal glucose levels. In analyses stratified by 
sex and age group, the CVD risk estimates tended to be 
higher in women than in men and in those <65 years of 
age but no significant interactions were found.
Conclusion An increase in casual blood glucose levels, 
even within the range of normal and borderline levels, 
was positively associated with increased risk of CVD and 
mortality among community- dwelling adults without a 
known diagnosis of diabetes.
INTRODUCTION
Diabetes is an increasing public health 
problem, and when uncontrolled, it has 
serious consequences for individuals’ health 
and well- being.1 Diabetes is well known to be 
a key risk factor for cardiovascular disease 
(CVD) and premature death.1–6 Further-
more, suboptimal blood glucose levels are 
associated with increased risk of coronary 
heart disease and strokes.2 It is not clear, 
however, whether glucose levels may predict 
CVD risk among individuals without known 
diabetes and, furthermore, whether casual 
blood glucose levels may predict CVD in the 
same way as fasting glucose levels. Such knowl-
edge is of relevance for general practitioners 
since the majority of individuals at risk of 
diabetes and CVD are treated in the primary 
care service. From an individual’s perspec-
tive, better glycemic control may prevent, or 
at least delay, CVD complications, which will 
have a great impact on the individual’s health 
and well- being.
In the UK, more than one- third of the 
adult population have pre- diabetes, which 
puts people at high risk of developing 
diabetes and CVD.7 Pre- diabetes may be 
defined as increased blood glucose levels that 
are not yet high enough to be diagnosed as 
diabetes.8 The metabolic process that leads to 
elevated blood glucose in individuals at risk 
of developing diabetes typically starts years 
before the diagnosis,9 and several trials have 
Significance of this study
What is already known about this subject?
 ► Suboptimal fasting blood glucose levels are associ-
ated with increased risk of coronary heart disease 
and strokes.
What are the new findings?
 ► Increase in casual blood glucose levels, even within 
the range of normal and borderline levels, is posi-
tively associated with increased risk of cardiovascu-
lar disease and mortality.
How might these results change the focus of 
research or clinical practice?
 ► The current study emphasizes that the risk of car-
diovascular disease starts before the diagnostic cut- 
off point for diabetes and that screening for casual 
blood glucose levels, also among those who are not 
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demonstrated that early identification and intervention 
in relation to high- risk individuals can prevent or delay 
the development of diabetes and its complications.10–12 
Finally, when assessing hyperglycemia and CVD risk 
among men and women without diabetes, studies often 
require participants to be fasting for blood sampling 
purposes. In some settings, however, it is unrealistic to 
require all participants to be fasting, for instance, in 
community- based studies. Moreover, people are seldom 
fasting when they visit their general practitioner with 
various health problems or for routine annual consulta-
tions for adults. It is therefore important to investigate 
whether casual blood glucose level (ie, no instructions to 
participants as regards fasting) is associated with future 
CVD risk.
To our knowledge, studies examining the association 
between casual blood glucose and future risk of CVD 
in both women and men, especially in older adults, are 
missing. In Norway, health data from several regional 
community- based health surveys of more than 170 000 
individuals are combined in the Cohort of Norway 
(CONOR) database.13 In the current study, CONOR was 
linked to the Cardiovascular Disease in Norway Project 
(CVDNOR), which includes information on all hospital 
stays with a cardiovascular or diabetes- related diagnosis 
from 1994 to 2009. Using these data, we aimed to assess 
the association between casual blood glucose level and 
subsequent CVD and mortality among community- 
dwelling adults without a known diagnosis of diabetes. 




By using the national identification number that is 
unique to every Norwegian resident, we linked informa-
tion in the CONOR database to the CVDNOR project 
in order to study the association between casual blood 
glucose level and future CVD and/or mortality. CONOR 
contains health data and blood sample data from various 
regional health surveys conducted from 1994 to 2003.13 
The CONOR database includes information obtained 
from self- administered questionnaires, physical examina-
tions, and results of analyses of biological samples.
CVDNOR (https:// cvdnor. w. uib. no/) was established 
as a collaborative research project between the University 
of Bergen and the Norwegian Knowledge Centre for the 
Health Services (now part of the Norwegian Institute of 
Public Health). Information on all hospital stays with a 
cardiovascular or diabetes- related diagnosis was retrieved 
from the electronic Patient Administrative Systems from 
1994 to 2009.14 15 Data include patients’ age at hospitaliza-
tion, the time and date of hospitalization and discharge, 
main and secondary diagnoses (up to 20), and medical 
procedures (up to 30) performed during the hospital 
stay.
Study population
A total of 174 322 men and women participated in 
a CONOR survey from 1994 to 2003. We excluded 
participants with a previous diagnosis of acute myocar-
dial infarction (AMI) or stroke (n=9371), allowing us 
to examine incident (first) events. Participants with 
known diabetes mellitus (n=4205) or who used antidi-
abetic medication (n=10) were also excluded, as were 
participants with blood glucose, cholesterol, weight, 
height or systolic blood pressure values under/above the 
0.1/99.9% percentile (n=1005). The numbers of partic-
ipants with missing data for each variable of interest 
after exclusions were as follows: serum glucose: 25 544 
(16.0%), marital status: 573 (0.4%), educational level: 28 
698 (18.0%), cholesterol: 259 (0.2%), systolic blood pres-
sure: 427 (0.3%), body mass index (BMI): 4774 (0.5%), 
smoking: 1697 (1.1%), and time since last meal: 7967 
(5.0%). Using multiple imputation (see statistical anal-
yses below), the final sample consisted of 159 731 partici-
pants: 69 148 women and 61 853 men.
Exposure and endpoints
The exposure for the current study was casual blood 
glucose measured at participation date in CONOR, 
examined both as a continuous and a categorical variable 
(normal <7.8 mmol/L, borderline 7.8–11.0 mmol/L, 
and high >11.0 mmol/L).
The endpoints include cardiovascular and all- cause 
mortality, as well as incident AMI and strokes. AMI was 
defined as a hospitalization with an AMI as the discharge 
diagnosis (International Classification of Diseases 
(ICD)-9 codes 410; ICD-10 codes I21–I22) or out- of- 
hospital death from coronary heart disease (ICD-9 codes 
410–414; ICD-10 I20–25). Stroke was defined as a hospi-
talization with, or death from, a stroke (ICD: ICD-9 codes 
430–434 and 436; ICD-10 codes I60–I61 and I63–I64, 
except I63.6). CVD mortality was defined as ICD-9 codes 
390–459 and ICD-10 codes I00–I99.
Statistical analyses
The relationship between blood glucose and study 
outcomes was modelled using Cox proportional hazard 
regression, and the results are reported as HRs with 95% 
CIs. Follow- up time was calculated as the time from the 
participation date in CONOR until the study endpoint 
or 31 December 2009 (whichever occurred first). Blood 
glucose was introduced in the models as: (1) a three- level 
categorical variable (using the category <7.8 mmol/L as 
the reference) and (2) a continuous variable.
Glucose was introduced as a continuous variable 
using two different approaches: (1) we estimated the 
HR associated with a 1 mmol/l increment in glucose by 
including glucose as a continuous variable in the Cox 
model, assuming one common slope for the entire range 
of glucose values; and (2) we allowed for different slopes 
within each glucose category by modelling continuous 
glucose levels as linear splines with knots at 7.8 mmol/L 
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categories, we estimated the HR associated with a 1 
mmol/L increase in glucose levels.
In addition to analyses for the total study sample, we 
tested for potential interaction between glucose levels 
and sex and age group (≤65 and >65 years). The propor-
tional hazard assumption was checked by inspecting log- 
(log) survival plots for categorical data and by using the 
estat phtest for continuous variables.
The following potential confounding variables were 
included in the models: age (years), sex, educational level 
(basic, upper secondary or tertiary education), marital 
status (married/cohabitant or other), daily smoking (yes 
or no), BMI (kg/m2), time since last meal (hours), total 
cholesterol (mmol/L), and systolic blood pressure (mm 
Hg). Age, cholesterol, blood pressure, and BMI were 
adjusted as linear variables in the models.
Multiple imputation by chained equations was 
used to address missing data for relevant variables.16 
Serum blood glucose was not measured in one of the 
health surveys included in CONOR, and missing data 
for glucose are therefore considered to be missing 
completely at random. For the current study, we imputed 
missing values for the exposure variable blood glucose 
(15.4%), as well as for marital status (0.4%), educational 
level (18%), cholesterol (0.2%), systolic blood pres-
sure (0.3%), smoking (1.1%), BMI (0.3%), and time 
since last meal (5.0%). Imputation was done separately 
for each endpoint and each representation of glucose 
(categorical or continuous), with stratification by sex 
and age group. We created 20 imputed datasets for each 
combination of endpoint and glucose representation. 
Imputation models included endpoint variables (binary 
endpoint- variable and time- variable) and all potential 
confounders. Continuous variables (glucose, cholesterol, 
systolic blood pressure, BMI, and time since last meal) 
were imputed using linear regression, ordinal categorical 
variables (glucose category and level of education) were 
imputed using ordinal logistic regression, and binary 
variables (smoking, marital status) were imputed using 
binary logistic regression. The average relative variance 
reports the average relative increase in variance of the 
estimates due to the missing values. It varied from 0.0572 
to 0.1357 in the present study. The closer this number is 
to zero, the less effect missing data have on the variance.17
The level of significance was defined as <0.05 and 
STATA V.16 was used in all analyses.
Ethical considerations
All CONOR survey participants signed a written informed 
consent to research and linkage of their data to health 
registries.
RESULTS
Sociodemographic and health characteristics of the 
CONOR survey participants (n=159 731) are presented 
in table 1. A total of 69 148 (82.3%) women had normal 
glucose levels, while 1152 (1.4%) had borderline levels 
and 126 (0.2%) had high levels. The corresponding 
numbers for men were 61 853 (81.7%), 1692 (2.2%) and 
216 (0.3%), respectively.
Both women and men with high glucose levels were 
older at the time of enrollment in CONOR (64.9 years 
vs 48.3 years among women and 57.7 years vs 49.6 years 
among men) and had less education compared with 
those with normal glucose levels (table 1). Compared 
with women with normal glucose levels, women with high 
levels had higher serum total cholesterol (6.3 mmol/L vs 
5.7 mmol/L) and higher systolic blood pressure (152.8 
mm Hg vs 129.8 mm Hg), and a higher proportion had 
obesity (52.3% vs 15.5%). Women with the highest levels 
of glucose smoked less (17.5%) than women with normal 
(29.7%) or borderline (26.1%) glucose levels. Similar 
results were found for men. Compared with men with 
normal glucose levels, those with high levels had higher 
serum total cholesterol (6.1 mmol/L vs 5.8 mmol/L) and 
higher systolic blood pressure (149.0 mm Hg vs 136.3 
mm Hg), and a higher proportion had obesity (41.2% 
vs 13.4%). In men, however, the highest proportion of 
smokers was found among those with borderline levels 
of glucose.
Multivariable Cox regression models comparing 
glucose categories are presented in figure 1. Partici-
pants categorized as having a high glucose level showed 
an increased risk of a stroke (HR 1.79; 95% CI 1.31 to 
2.43), cardiovascular mortality (HR 1.90; 95% CI 1.42 to 
2.55), and all- cause mortality (HR 1.69; 95% CI 1.38 to 
2.05) when compared with those with a normal glucose 
level (figure 1). Individuals with borderline glucose levels 
also showed an increased risk compared with those with 
normal glucose levels, but HRs were somewhat weaker 
compared with high glucose levels. Cox models only 
adjusted for age, sex, and time since last meal instead 
of full adjustment are presented in online supplemental 
table S1. HRs were generally stronger in these models 
than in the fully adjusted models in figure 1. Sensitivity 
analyses on data without imputations are presented in 
online supplemental table S2 and are comparable with 
the results from analyses done on imputed data.
When analyzing glucose as a continuous variable, a 
1 mmol/L increase was associated with an increase in 
the risk of all endpoints, ranging from 3.0% to 16.0% 
(table 2). When using linear splines with knots at 7.8 
and 11.0 (allowing for different linear slopes within 
each category), we observed that a 1 mmol/L increase 
in glucose levels was associated with a statistically signifi-
cant increased risk of AMI, stroke and CVD, and all- cause 
mortality in participants with glucose levels <7.8 mmol/L, 
and in the risk of a stroke, CVD, and all- cause mortality in 
participants with glucose levels between 7.8 mmol/L and 
11.0 mmol/L (table 2). The association between glucose 
levels and study endpoints was not significant in partici-
pants with glucose levels >11.0 mmol/L.
In analyses stratified by sex, we observed higher risk 
estimates for high and borderline glucose versus normal 
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Table 1 Sociodemographic and health characteristics of 159 731 participants in Cohort of Norway from 1993 to 2004






(>11.0 mmol/L) P value* Missing†
Women (n=84 005)
No. (%) 69 148 (82.3) 1152 (1.4) 126 (0.2) 13 579 (16.2)
Age, mean (SD) 48.3 (15.0) 58.5 (15.5) 64.9 (16.3) <0.001 46.8 (15.0)
Marital status, n (%) 0.070
  Married/registered partnership 41 460 (59.1) 680 (59.1) 63 (50.0) 7195 (53.1)
  Other 27 602 (39.9) 471 (40.9) 63 (50.0) 6356 (46.9)
Education, n (%) <0.001
  Basic education 17 614 (31.0) 431 (48.4) 50 (64.9) 4854 (36.0)
  Upper secondary education 22 627 (39.8) 294 (33.0) 20 (26.0) 4735 (35.1)
  Tertiary education 16 547 (29.1) 165 (18.5) 7 (9.1) 3897 (28.9)
Serum glucose, mmol/L, mean (SD) 5.1 (0.7) 8.6 (0.8) 13.8 (2.4) <0.001 –
Serum total cholesterol, mmol/L, mean (SD) 5.7 (1.2) 6.1 (1.3) 6.3 (1.3) <0.001 6.0 (1.3)
Current smoker 20 562 (29.7) 301 (26.1) 22 (17.5) 0.002 4986 (36.7)
Systolic blood pressure, mean (SD) 129.8 (21.1) 141.3 (24.1) 152.8 (24.6) <0.001 130.8 (21.4)
BMI, mean (SD) 25.7 (4.4) 27.4 (5.1) 31.2 (6.2) <0.001 24.7 (4.2)
Obesity 10 670 (15.5) 307 (27.7) 57 (52.3) <0.001 1452 (10.7)
Time since last meal, mean (SD) 1.9 (1.4) 1.0 (1.1) 1.6 (1.3) <0.001 2.2 (1.5)
Endpoints, n (%)
  Acute myocardial infarction 1637 (2.4) 66 (5.7) 13 (10.3) <0.001 472 (3.5)
  Stroke 2187 (3.2) 96 (8.3) 19 (15.1) <0.001 573 (4.2)
  Cardiovascular death 1983 (2.9) 109 (9.5) 22 (17.5) <0.001 539 (4.0)
  All cause death 5850 (8.5) 243 (21.1) 49 (38.9) <0.001 1614 (11.9)
Men (n=75 726)
No. (%) 61 853 (81.7) 1692 (2.2) 216 (0.3) 11 965 (15.8)
Age, mean (SD) 49.6 (15.0) 57.5 (14.3) 57.7 (14.1) <0.001 46.0 (13.9)
Marital status, n (%) <0.001
  Married/cohabitant 39 098 (63.4) 1235 (73.1) 135 (62.5) 6652 (55.8)
  Other 22 338 (36.3) 454 (26.9) 81 (37.5) 5275 (44.2)
Education, n (%) <0.001
  Basic education 11 448 (24.6) 423 (35.8) 62 (42.5) 3494 (29.4)
  Secondary education 21 161 (45.4) 465 (39.3) 56 (38.4) 4509 (37.9)
  Tertiary education 13 965 (30.0) 294 (24.9) 28 (19.8) 3887 (32.7)
Serum glucose, mmol/L, mean (SD) 5.3 (0.8) 8.7 (0.8) 13.9 (2.5) <0.001 –
Serum total cholesterol, mmol/L, mean (SD) 5.8 (1.1) 5.9 (1.1) 6.1 (1.2) <0.001 6.0 (1.2)
Current smoker 17 910 (29.0) 553 (32.7) 66 (30.6) <0.001 4533 (37.9)
Systolic blood pressure, mean (SD) 136.3 (17.8) 144.7 (21.0) 149.0 (21.1) <0.001 136,5 (16.7)
BMI, mean (SD) 26.3 (3.4) 27.2 (4.0) 29.3 (5.0) <0.001 25.5 (3.3)
Obesity 8239 (13.4) 369 (22.1) 85 (41.2) <0.001 1070 (9.0)
Time since last meal, mean (SD) 2.0 (1.5) 1.0 (1.1) 1.6 (1.5) <0.001 2.3 (1.6)
Endpoints, n (%)
  Acute myocardial infarction 3394 (5.5) 145 (8.6) 21 (9.7) <0.001 821 (6.9)
  Stroke 2498 (4.0) 131 (7.7) 23 (10.7) <0.001 590 (4.9)
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with men (table 3). The stronger HRs were especially 
apparent for subsequent risk of AMI for high glucose 
versus normal glucose with a multivariable- adjusted HR 
of 1.79 (95% CI 1.03 to 3.12) for women compared with 
1.14 (95% CI 0.74 to 1.75) for men. Interaction tests for 
effect modification by sex were not significant for any of 
the endpoints.
Results from analyses stratified by age (<65 and ≥65 
years) are presented in online supplemental table S3. 
In participants younger than 65 years of age, we found 
an increased risk of a stroke (HR 1.77; 95% CI 1.01 to 
3.09), cardiovascular mortality (HR 2.66; 95% CI 1.45 to 
4.89), and all- cause mortality (HR 1.68; 95% CI 1.07 to 
2.56) when we compared those with high versus normal 
glucose levels. In participants aged 65 years and above, we 
observed a 60%–70% increased risk of all four endpoints 
for participants with high compared with normal glucose 
levels. Similar results, except for AMI, were found for 
participants aged 65 years and above with a borderline 
glucose level. Interaction tests for effect modification by 
age group were not significant for any of the endpoints.
CONCLUSIONS
The results of the current study indicate that casual 
blood glucose level is a significant predictor of CVD and 
mortality among community- dwelling adults without a 
known diagnosis of diabetes. A linear increasing risk per 
1 mmol/L increase in glucose level among participants 
with both normal and borderline glucose levels was found 
for AMI, stroke, and cardiovascular as well as all- cause 
mortality. The analyses also revealed higher relative risk 
estimates for all four endpoints in women compared with 
men, although not significantly higher. Furthermore, no 
clear pattern was found when stratifying the analyses by 
age group (<65 versus ≥65 years).
Comparison with other studies
Limited evidence is available on the association between 
casual blood glucose level and future CVD risk. In the 
current study, subjects without diagnosed diabetes but 
with blood glucose levels higher than normal, as well as 
borderline glucose levels below the diagnostic threshold 
for diabetes, were found to be at increased risk of CVD 
and mortality. The associations remained but were weaker 
after multivariable adjustment for other CVD risk factors. 
The mechanism behind the association between glucose 
level and future CVD remains uncertain, but results from 
in vitro and animal studies have suggested that, together, 
increased glucose levels, free fatty acids, and insulin resis-
tance lead to, for example, oxidative stress and activation 
of protein kinase C isoform, which may further result in 
vasoconstriction, inflammation, and thrombosis.18 19
The results of the current study are consistent with the 
meta- analysis by Levitan et al,20 who analyzed 38 prospec-
tive observational studies and identified hyperglycemia 
in persons without a diagnosis of diabetes as a risk 
marker for CVD. They did, however, include studies with 
different measures of blood glucose (postload glucose, 
casual glucose, fasting glucose, or hemoglobin A1c), of 
which only four studies used casual blood glucose. A 
meta- analysis from 2011 that included a variety of study 
designs found no evidence of an association between 
casual blood glucose level and CVD.21 A later study by 
Imano et al22 from 2012 observed an increased risk of 
coronary heart disease in individuals with borderline and 
high glucose levels. This study did have a notably smaller 






(>11.0 mmol/L) P value* Missing†
  All- cause mortality 7267 (11.8) 398 (23.5) 61 (28.2) <0.001 1614 (13.5)
Number of missing: marital status: 573 (0.4%), education: 28 698 (18.0%), cholesterol: 259 (0.2%), systolic blood pressure: 427 (0.3%), BMI: 
774 (0.5%), smoking: 1697 (1.1%), and time since last meal: 7967 (5.0%).
*Test for trend by comparing participants with normal, borderline, and high casual blood glucose. Regress for continuous variables and logit/
ologit for categorical variables.
†Persons with missing data on casual glucose level (before imputation).
BMI, body mass index.
Table 1 Continued
Figure 1 Casual blood glucose and risk of fatal or nonfatal 
acute myocardial infarction, stroke, cardiovascular mortality 
and all- cause mortality in 159 731 Norwegian men and 
women, followed up to 12.7 years (imputed data). All 
analyses adjusted for age, sex, cholesterol, systolic blood 
pressure, BMI, time since last meal, smoking, education and 
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study population (n=7332) than ours (n=1 59 731), and 
it only included individuals aged 40–69 years of age. 
Similar results were also found in the study by Kadowaki 
et al23 from 2008, which analyzed more than 450 000 men 
and women aged 30 years and above.
In the current study, we also found a linear increasing 
risk per 1 mmol/L increase in glucose level among partic-
ipants with both normal and borderline glucose levels for 
all four endpoints. This is in accordance with two Asian 
studies from 2008 and 2016.23 24 Thus, the use of casual 
glucose measurements in general practice might be an 
important marker for further follow- up to identify people 
at risk of diabetes and CVD many years before diagnosis. 
Such early identification of high- risk individuals can 
delay the development of diabetes and its complications. 
Nevertheless, few previous studies have examined the 
association between casual blood glucose levels and CVD 
risk in large community- based studies, which was the 
motivation for conducting the current study.
Differences between men and women
When looking at differences in CVD risk between the 
sexes, the risk estimates tended to be higher for all 
endpoints among women than among men in subjects 
with borderline or high glucose levels. These results 
are consistent with previous studies20 22 and indicate 
that hyperglycemia may be a stronger CVD risk factor 
among women than among men. The manifestations of 
CVD vary between the sexes, and it is well known that 
CVD risk among individuals with diabetes varies between 
the sexes.25 26 Women appear to be more susceptible to 
hyperglycemia than men, and hyperglycemia may be 
associated with different CVD risk factors among women 
than among men.20 27 Extensive statistical adjustment for 
CVD risk factors does not seem to explain the observed 
sex differences, which may suggest that hyperglycemia 
cancels out some of the protective effect of female sex 
as regards CVD risk.20 Nevertheless, it is well known that 
men develop CVD at a younger age and have a higher 
risk of developing coronary heart disease than women.28 
When using relative effect measures such as HRs, the 
differences between men and women will be exagger-
ated because the same absolute risk increase will result 
in a higher relative risk increase among women. Also, in 
the current study, there were few individuals with high 
glucose level and we can therefore not rule out that the 
different effect of glucose level on CVD risk between the 
sexes would change if we had a larger study sample and 
thereby more statistical power.
Age differences
There is a lack of studies examining the association 
between casual blood glucose and future risk of CVD in 
older individuals. Only one29 of the four studies assessing 
casual glucose in the meta- analysis from 200420 included 
participants aged 65 years and above and that study had a 
short follow- up period (<5 years), fewer than 3000 study 
participants and no statistical adjustment for CVD risk 
factors. The study by Imano et al from 2012 included 
men and women aged 40–60 years,22 while Kadowaki et 
al23 included participants aged 30 years and above. None 
of these three studies looked at potential age differences 
in relation to CVD risk with increasing glucose level. The 
Chinese study from 2016 by Bragg et al24 found a more 
or less similar risk of CVD mortality and major occlusive 
vascular disease in those with high glucose levels aged 
35–59, 60–69, and 70–79 years, although with some indi-
cation of stronger associations with CVD risk among the 
youngest. Moreover, it has been found that, while those 
aged 51–60 years with diabetes have approximately a 
2.5- fold higher risk of coronary heart disease than those 
without diabetes, those aged 31–40 years with diabetes 
have an approximately 17 times higher risk than individ-
uals without diabetes.30 Furthermore, a study from the 
USA found that young (18–39 years of age) and middle- 
aged (40–64 years of age) individuals have substantially 
Table 2 HRs with 95% CIs per 1 mmol/L increase in casual glucose levels from Cox proportional hazards models* with 
glucose analyzed as a continuous variable with and without linear splines in 159 731 Norwegian men and women, followed up 
to 12.7 years (imputed data)
Events/no.
HR (95% CI) for model with linear splines with three knots













6569/159 731 1.03 (1.00 to 1.07) 1.01 (0.92 to 1.12) 1.06 (0.96 to 1.18) 1.03 (1.01 to 1.06)
Stroke 6117/159 731 1.03 (1.00 to 1.07) 1.16 (1.06 to 1.28) 0.98 (0.89 to 1.09) 1.05 (1.03 to 1.07)
Cardiovascular 
mortality
5678/159 731 1.06 (1.02 to 1.10) 1.11 (1.01 to 1.22) 1.04 (0.95 to 1.13) 1.07 (1.04 to 1.09)
All- cause mortality 17,096/159 731 1.05 (1.03 to 1.08) 1.13 (1.07 to 1.19) 1.00 (0.94 to 1.06) 1.06 (1.05 to 1.08)
*Adjusted for age, sex, cholesterol, systolic blood pressure, BMI, time since last meal, smoking, education and marital status.
†HR per mmol/L increase in casual glucose levels with 95% CI.
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higher glycemic levels than older adults.10 In the current 
study, there was no clear effect modification by age for 
the association between glucose level and subsequent 
CVD and mortality. For AMI, the association was only 
significant for high glucose levels among those 65 years 
and older, while the association with cardiovascular 
mortality was most pronounced among those younger 
than 65 years of age. For strokes and all- cause mortality, 
only small differences were found between the two age 
groups with slightly stronger associations among those 
younger than 65 years. There was no significant interac-
tion effect between age group and glucose for any of the 
endpoints, but given the small number of individuals and 
endpoints in the highest glucose category, this could be 
a consequence of low power. Taken together, these find-
ings may imply that the association between casual blood 
glucose and future risk of CVD is strongest among the 
youngest, although no firm conclusions can be drawn 
based on currently available research.
Strengths and weaknesses
The strength of the current study includes its community- 
based cohort design and its use of information on 
glucose level and subsequent risk of CVD and mortality 
to conduct a large study of men and women without a 
known diagnosis of diabetes. We were able to investi-
gate differences according to sex and age group and to 
adjust for the effect of several CVD risk factors. Some 
Table 3 Casual blood glucose and risk of incidence of fatal or non- fatal acute myocardial infarction and stroke and 
cardiovascular and all- cause mortality in 159 731 Norwegian men and women, followed up to 12.7 years, stratified by sex 
(imputed data)
Events/no.
Baseline casual blood glucose level
<7.8 mmol/L (normal) 7.8–11.0 mmol/L (borderline) >11.0 mmol/L (high)
Acute myocardial infarction
Women 2188/84 005
  Adjusted HR (95 % CI)* 1 (ref.) 1.37 (1.07 to 1.76) 1.98 (1.14 to 3.44)
  Adjusted HR (95% CI)† 1 (ref.) 1.30 (1.02 to 1.68) 1.79 (1.03 to 3.12)
Men 4381/75 726
  Adjusted HR (95% CI)* 1 (ref.) 1.13 (0.95 to 1.35) 1.33 (0.87 to 2.03)
  Adjusted HR (95% CI)† 1 (ref.) 1.05 (0.88 to 1.26) 1.14 (0.74 to 1.75)
Stroke
Women 2875/84 005
  Adjusted HR (95% CI)* 1 (ref.) 1.46 (1.17 to 1.81) 2.18 (1.38 to 3.45)
  Adjusted HR (95% CI)† 1 (ref.) 1.39 (1.11 to 1.73) 1.93 (1.21 to 3.05)
Men 3242/75 726
  Adjusted HR (95% CI)* 1 (ref.) 1.33 (1.12 to 1.60) 1.87 (1.24 to 2.83)
  Adjusted HR (95% CI)† 1 (ref.) 1.23 (1.03 to 1.47) 1.66 (1.09 to 2.53)
Cardiovascular mortality
Women 2653/84 005
  Adjusted HR (95% CI)* 1 (ref.) 1.53 (1.25 to 1.87) 2.17 (1.40 to 3.35)
  Adjusted HR (95% CI)† 1 (ref.) 1.48 (1.22 to 1.81) 1.99 (1.29 to 3.07)
Men 3025/75 726
  Adjusted HR (95% CI)* 1 (ref.) 1.25 (1.04 to 1.51) 1.98 (1.33 to 2.93)
  Adjusted HR (95% CI)† 1 (ref.) 1.16 (0.97 to 1.40) 1.81 (1.21 to 2.70)
All- cause mortality
Women 7756/84 005
  Adjusted HR (95% CI)* 1 (ref.) 1.29 (1.13 to 1.47) 1.89 (1.42 to 2.52)
  Adjusted HR (95% CI)† 1 (ref.) 1.27 (1.12 to 1.45) 1.83 (1.36 to 2.46)
Men 9340/75 726
  Adjusted HR (95% CI)* 1 (ref.) 1.29 (1.17 to 1.44) 1.64 (1.27 to 2.12)
  Adjusted HR (95% CI)† 1 (ref.) 1.27 (1.14 to 1.41) 1.59 (1.22 to 2.08)
*Adjusted for age and time since last meal.
†Adjusted for age, cholesterol, systolic blood pressure, BMI, time since last meal, smoking, education and marital status.
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limitations also need to be addressed. First, this study was 
based on one single blood glucose measurement and not 
two, which is recommended in clinical guidelines. Thus, 
the results may not accurately reflect an individual’s usual 
or longer term glucose and thereby indicate values over 
the diagnostic threshold. Moreover, no information was 
available about subsequent diabetes diagnoses among 
those with borderline or high glucose levels, and we were 
therefore unable to examine whether the increased CVD 
risk among these individuals was mediated by diabetes. 
There may also be individuals with undiagnosed diabetes 
at baseline. Second, by using casual glucose level, we had 
information on both fasting and non- fasting individuals, 
and although only 0.2% of the study population reported 
that it had been more than 7 hours since their last meal, 
it may not be suitable to categorize these individuals 
according to the same glucose categories as non- fasting 
participants. Compared with fasting glucose levels, casual 
levels may have larger intraindividual and interindividual 
variations due to the influence of sampling time (eg, time 
since last meal).24 Also, previous studies have shown that 
both HbA1c and fasting blood glucose independently 
predict CVD.31–33 However, Hemoglobin A1c (Hba1c) 
and blood glucose measure different aspects of glucose 
metabolism; HbA1c measures chronic glycemia, while 
blood glucose reflects glucose at the time of sampling. 
These two measures therefore identify different individ-
uals at risk of CVD. Casual glucose has the advantage 
of lower costs and higher feasibility. Third, we imputed 
missing values for the main exposure variable: casual 
blood glucose. For the majority of the participants with 
missing glucose levels, the values were missing completely 
at random, because one of the regional health surveys 
in CONOR did not include measurement of glucose. 
For the remaining participants with missing values, it 
is reasonable to assume them to be missing at random 
given the other cardiovascular risk factors included in the 
model. We therefore do not believe that the imputation 
could have introduced any substantial bias. Lastly, there 
were considerable differences in baseline characteristics 
across categories of glucose levels and even though we 
have adjusted for confounding by using multiple regres-
sion, we cannot rule out that the associations found in 
the current study may be due to residual confounding 
because of imbalance between categories. The observed 
associations between continuous glucose and CVD risk 
within the normal and borderline range of glucose is 
however less prone to residual confounding caused by 
failure to reach covariate balance.
In conclusion, the current study found an association 
between elevated casual blood glucose level, even within 
the range of normal and borderline levels, and future 
CVD and mortality among adults without a known diag-
nosis of diabetes. These findings point to the importance 
of early identification of individuals at risk of diabetes 
and subsequent CVD. Screening for casual blood glucose 
levels also among those who are not suspected of having 
diabetes may be important from a public health viewpoint.
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